Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC

NCT06768255 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Abiraterone Acetate
MCRPC (metastatic Castration-resistant Prostate Cancer)

Interventions

DRUG: Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT
DRUG: Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT

Sponsor

Ding-Wei Ye